"10.1371_journal.pone.0080003","plos one","2013-11-20T00:00:00Z","Jordan J Feld; Jason Grebely; Gail V Matthews; Tanya Applegate; Margaret Hellard; Alana Sherker; Vera Cherepanov; Kathy Petoumenos; Barbara Yeung; John M Kaldor; Andrew R Lloyd; Gregory J Dore","Toronto Centre for Liver Disease, McLaughlin-Rotman Centre for Global Health, University of Toronto, Toronto, Canada; The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia; HIV/Immunology/Infectious Diseases Clinical Services Unit, St Vincentâ€™s Hospital, Sydney, Australia; Burnet Institute, Melbourne, Australia; Infectious Diseases Unit, The Alfred Hospital, Melbourne, Australia; Inflammation and Infection Research Centre, School of Medical Sciences, University of New South Wales, Sydney, Australia","Conceived and designed the experiments: JJF JG GVM ARL GJD. Performed the experiments: JJF AS VC TA. Analyzed the data: JJF JG AAL GJD. Contributed reagents/materials/analysis tools: JJF VC AS TA MH KP BY JMK. Wrote the paper: JJF JG GVM ARL GJD. Evaluated study patients: GJD GVM MH ARL.","Roche Pharmaceuticals supplied financial support for pegylated IFN-alfa-2a/ribavirin for this study. JJF is consultant/advisor and/or has received research support from Abbott, Achillion, Boehringer-Ingelheim, Gilead, Janssen, Merck, Roche and Vertex. JG is a consultant/advisor for Merck and has received research grants from Roche and Merck. GD is a consultant/advisor and has received research grants from Roche, Merck, Janssen, Gilead, Bristol Myers Squibb. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","11","Jordan J Feld","JJF",12,TRUE,5,4,4,5,TRUE,TRUE,FALSE,0,NA,FALSE
